Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 5/20 | 0.48 |
| ▸ | RAF1 | P04049 | 7/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | CIT | O14578 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MUSK | O15146 | 1/20 | 0.40 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878029 | 0.85 | CDK8 (0.48) | CDK8RAF1KDRPLA2G7PIK3CA | |
| SCHEMBL29985730 | 0.80 | AR (0.46) | CDK8RAF1KDRBRAFCHEK2 | |
| SCHEMBL875004 | 0.80 | AR (0.46) | CDK8RAF1KDRBRAFCHEK2 | |
| SCHEMBL883449 | 0.80 | CHEK2 (0.46) | CDK8RAF1KDRBRAFCHEK2 | |
| SCHEMBL876289 | 0.78 | CHEK2 (0.47) | CDK8RAF1KDRBRAFCHEK2 | |
| SCHEMBL876144 | 0.78 | CDK8 (0.46) | CDK8RAF1KDRPLA2G7PIK3CA | |
| SCHEMBL875734 | 0.78 | AR (0.51) | CDK8KDRPLA2G7PIK3CAAR | |
| SCHEMBL875480 | 0.77 | ALDH1A1 (0.62) | CDK8KDRPLA2G7BRAF | |
| SCHEMBL14656154 | 0.77 | CDK8 (0.48) | CDK8RAF1KDRPLA2G7PIK3CA | |
| SCHEMBL14656102 | 0.77 | CDK8 (0.67) | CDK8RAF1KDRPIK3CABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| EP-2619203-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | Glaxo Group Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | CDK8 681/4885RAF1 2513/4885KDR 1285/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | CDK8 681/4885RAF1 2513/4885KDR 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.